FOXO TECHNOLOGIES, INC., FORMS STRATEGIC PARTNERSHIP WITH LONGEVITYFP TECHNOLOGIES, LLC. TO COMMERCIALIZE FOXO’S EPIGENETICS TECHNOLOGY
FOXO Technologies has entered an exclusive license agreement with LongevityFP Technologies, LLC, to commercialize its epigenetics technology. LongevityFP, owned by former FOXO CEO Jon Sabes, will pay FOXO a 3% royalty on net revenues, capped at $1.3 million in aggregate. The deal also grants LongevityFP a 10-year option to acquire majority ownership of FOXO Labs, FOXO’s biotech subsidiary, in exchange for a 40% equity stake in the resulting enterprise.
Key figures
- Option term
- 10 years
- Royalty cap
- $1.3 million
- Royalty rate
- 3%
- Equity upside
- 40%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.